OncoSil Medical secures US FDA approval for OncoSil device, opening A$80 million annual market
Kort samengevat
OncoSil Medical Ltd (ASX:OSL, OTC:OCMLF) has secured US Food and Drug Administration (FDA) approval for its OncoSil™ targeted radiation device to treat distal cholangiocarcinoma (dCCA), giving the company US marketing authorisation and opening an estimated A$80 million annual addressable market.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Proactiveinvestors UK.
Lees het volledige bericht ↗